Quick Answer
The FDA has stepped up enforcement on compounded GLP-1 drugs in 2026. New warning letters, tighter rules on salt forms, and increased inspections of compounding facilities mean the legal landscape is shifting. If you use or are considering compounded GLP-1s, here is what changed and what it means for you.
Key Points
- FDA enforcement is intensifying — More warning letters and inspections targeting GLP-1 compounders in 2026
- Salt forms remain the biggest concern — The FDA still considers semaglutide sodium/acetate salts different active ingredients
- Shortage status drives legality — Compounding is only permitted when the FDA lists the drug as in shortage
- Tirzepatide compounding faces new restrictions — As Eli Lilly resolves some dose shortages, the FDA is telling compounders to stop
- Telehealth platforms under scrutiny — Several online sellers have received cease-and-desist notices
- Patient protections are limited — Compounded drugs do not carry the same legal protections as FDA-approved medications
What Changed in 2026
FDA Warning Letters Continue
The FDA has kept up its enforcement pace from 2025 into 2026. Key actions include:
- Warning letters to compounders using salt forms — The FDA reiterates that semaglutide sodium and semaglutide acetate are not the same as semaglutide base
- New letters targeting misleading marketing — Providers claiming "generic Ozempic" or "identical to Wegovy" have been flagged
- Actions against online sellers — Several telehealth platforms received cease-and-desist letters for selling compounded GLP-1s without valid prescriptions or proper pharmacy oversight
Shortage List Status Updates
The FDA drug shortage list changes frequently. Here is where things stand as of April 2026:
- Semaglutide injection — Certain doses have rotated on and off the shortage list. When a dose comes off the list, compounders must stop producing it
- Tirzepatide — Eli Lilly has increased production. Some previously short doses are now available, which means the FDA expects compounders to stop making copies of those doses
- Ongoing monitoring — The FDA updates the shortage list regularly. Always check FDA.gov Drug Shortages for the latest status
503B Facility Inspections Increased
The FDA has increased inspection frequency for 503B outsourcing facilities that compound GLP-1 drugs. This means:
- More facilities are being inspected for compliance with current Good Manufacturing Practices (cGMP)
- Facilities found violating standards face warning letters, import alerts, or shutdowns
- Patients can check whether a 503B facility is registered with the FDA through the FDA 503B facility database
The Legal Landscape in 2026
When Compounding Is Legal
Compounded GLP-1 drugs are legal when all of these conditions are met:
- The drug is on the FDA shortage list
- The compounding pharmacy is properly licensed (503A or 503B)
- A valid prescription from a licensed healthcare provider is required
- The compounded product uses the correct active ingredient form (base, not salt)
- The pharmacy follows applicable state and federal regulations
When Compounding Is Not Legal
Compounding GLP-1s is illegal when:
- The drug is not on the FDA shortage list and the compounder continues producing it
- The product uses salt forms that the FDA has not approved
- No prescription is required
- The provider makes false claims ("generic Ozempic," "FDA-approved")
- The product is sold directly on social media without pharmacy oversight
State-Level Actions
Some states have taken their own enforcement actions in 2026:
- State pharmacy board investigations — Several states have investigated compounding pharmacies that violated state regulations
- Attorney general actions — A few state AGs have pursued cases against online sellers of compounded GLP-1s for deceptive marketing
- Telehealth regulation — States are tightening rules on telehealth platforms that prescribe compounded medications without adequate medical evaluation
What the FDA's Stance Means for You
If You Currently Use Compounded GLP-1s
- Verify your source — Ask your provider which pharmacy compounds your medication and check their credentials
- Confirm the ingredient form — Make sure you are getting semaglutide base, not a salt form
- Request a certificate of analysis — This document shows potency and purity testing results
- Watch for changes — If the shortage list status changes for your medication, your compounder may need to stop producing it
- Have a backup plan — Talk to your doctor about what to do if your compounded source becomes unavailable
If You Are Considering Compounded GLP-1s
- Try brand-name options first — Manufacturer savings programs can bring costs to $0-500/month for eligible patients. See our compounded GLP-1 overview for savings program details
- Choose a 503B facility — These have stricter FDA oversight than 503A pharmacies. See our compounded semaglutide safety guide for the full vetting checklist
- Demand transparency — If a provider cannot answer your questions about ingredient form, testing, or pharmacy credentials, walk away
- Budget realistically — Legitimate compounded semaglutide costs $200-500/month. Prices under $200/month are a red flag
If Your Compounded Source Shuts Down
If your compounding pharmacy is shut down by the FDA or stops producing GLP-1 drugs:
- Do not panic — You have options
- Talk to your doctor — They can help you transition to an FDA-approved medication or find a different legitimate compounder
- Do not skip doses abruptly — Work with your healthcare provider on a transition plan
- Check insurance coverage — Coverage has expanded in 2026. You may now qualify for brand-name medication. See our insurance guide
- Report adverse events — If you experienced problems with a compounded product, report them to the FDA MedWatch program
Key Differences: FDA-Approved vs. Compounded GLP-1s
| Feature | FDA-Approved | Compounded |
|---|---|---|
| Safety testing | Rigorous clinical trials | Not required |
| FDA oversight | Full approval process | Limited (503B) or state-level (503A) |
| Manufacturing standards | cGMP required | Varies by facility |
| Active ingredient form | Semaglutide base | May be base or salt forms |
| Legal protections | Full product liability | Limited recourse |
| Cost (no insurance) | $900-1,400/month | $200-500/month |
| Cost (with savings) | $0-500/month | $200-500/month |
Red Flags in 2026
Watch for these warning signs that a compounded GLP-1 provider may not be legitimate:
- Prices under $200/month — Likely salt forms or corner-cutting
- No prescription required — Illegal and dangerous
- "Generic Ozempic" claims — No FDA-approved generic exists for weight loss
- Social media sales — Compounded medications must come from licensed pharmacies
- Refusal to show testing results — Legitimate compounders provide certificates of analysis
- No pharmacy name or address — Every real pharmacy has one
- Pressure to buy quickly — "Limited supply" or "sale ending soon" tactics
What to Ask Your Doctor
- Is an FDA-approved GLP-1 medication available to me through savings programs or insurance?
- If I need compounded medication, which 503B pharmacy do you recommend?
- How will you monitor my response to compounded GLP-1?
- What is our plan if my compounded source becomes unavailable?
- Are there any new FDA-approved alternatives I should consider?
Looking Ahead
The regulatory environment for compounded GLP-1s will likely keep tightening through 2026 and beyond. As manufacturers expand production and resolve shortages, the legal basis for compounding these drugs narrows. At the same time, new FDA-approved GLP-1 medications are entering the market, giving patients more options.
The safest path is to use FDA-approved medications whenever possible. If cost or availability forces you toward compounding, verify your source thoroughly and stay informed about FDA enforcement actions.
For a broader overview of compounding risks and benefits, see our compounded GLP-1 guide. For the full pharmacy vetting checklist, see our compounded semaglutide safety guide.
The Bottom Line
The FDA is getting tougher on compounded GLP-1 drugs in 2026. Enforcement is up. Warning letters continue. And as shortages ease, the legal window for compounding narrows. If you use compounded GLP-1s, verify your source now. If you are considering them, explore brand-name savings programs first. And always talk to your doctor before making changes.
This article is for informational purposes only and does not constitute medical or legal advice. Always consult with a licensed healthcare provider before starting or changing any medication. Report adverse events from compounded products to the FDA MedWatch program. Check the FDA drug shortage database for the most current compounding legality status.